Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).
Hofbauer
L C
LC
Division of Gastroenterology and Endocrinology, Philipps-University, Marburg, Germany. hofbauer@post.med.uni-marburg.de
D000818:Animals; D001847:Bone Diseases / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D001862:Bone Resorption; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D004195:Disease Models, Animal; D005260:Female; D006023:Glycoproteins / Q000502:physiology*; D006801:Humans; D008562:Membrane Glycoproteins / Q000037:antagonists & inhibitors / Q000502:physiology*; D010010:Osteoclasts / Q000502:physiology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology*; D018124:Receptors, Tumor Necrosis Factor / Q000502:physiology*
D002352:Carrier Proteins; D006023:Glycoproteins; D008562:Membrane Glycoproteins; D053244:Osteoprotegerin; D053245:RANK Ligand; D053246:Receptor Activator of Nuclear Factor-kappa B; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C505686:TNFRSF11A protein, human; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human